Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsy.
- DOI
- 10.1016/j.ejca.2025.115372
- Published
- 2025-04-04
- Container
- Eur J Cancer
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejca.2025.115372,
title = {Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsy.},
author = {Amaral T and Chatziioannou E and Nuebling A and Nanz L and Sinnberg T and Niessner H and Arentsen T and Ruiter R and Dwarkasing J and Eggermont AM and Leiter U and Flatz L and Forchhammer S.},
year = {2025},
journal = {Eur J Cancer},
doi = {10.1016/j.ejca.2025.115372},
url = {https://doi.org/10.1016/j.ejca.2025.115372}
}RIS
TY - JOUR TI - Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsy. AU - Amaral T AU - Chatziioannou E AU - Nuebling A AU - Nanz L AU - Sinnberg T AU - Niessner H AU - Arentsen T AU - Ruiter R AU - Dwarkasing J AU - Eggermont AM AU - Leiter U AU - Flatz L AU - Forchhammer S. PY - 2025 JO - Eur J Cancer DO - 10.1016/j.ejca.2025.115372 UR - https://doi.org/10.1016/j.ejca.2025.115372 ER -
APA
T, A., E, C., A, N., L, N., T, S., H, N., T, A., R, R., J, D., AM, E., U, L., L, F., & S., F. (2025). Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsy.. Eur J Cancer. https://doi.org/10.1016/j.ejca.2025.115372
Source records
- europe-pmc · retrieved 2026-09-25T13:28:13.537Z